Related Experiment Video
Updated: Feb 8, 2026
07:49
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
2.0K
The Effect of Mecp2 on Heart Failure
Summary
Methyl-CpG-binding protein 2 (MeCP2) is downregulated in heart failure. Its dysregulation affects genes involved in cytoskeletal regulation and inflammation, offering potential therapeutic targets and prognostic markers for heart failure.
Area of Science:
- Cardiovascular Biology
- Epigenetics
- Molecular Medicine
Background:
- Heart failure (HF) is a critical endpoint of cardiovascular diseases with high morbidity and mortality.
- Epigenetic regulation plays a significant role in the pathogenesis of HF.
- Methyl-CpG-binding protein 2 (MeCP2) is a key epigenetic regulator implicated in various cellular processes.
Purpose of the Study:
- To investigate the effect of MeCP2 on heart failure.
- To identify genes and pathways regulated by MeCP2 in the context of heart failure.
- To explore the potential of MeCP2-associated genes as therapeutic targets or prognostic markers for HF.
Main Methods:
- Gene Ontology (GO) term and protein-protein interaction (PPI) network analyses were performed on heart failure-associated genes.
- Identification of significantly up- or downregulated genes in a heart failure animal model.
- Analysis of aberrantly expressed genes in relation to MeCP2 expression levels (overexpression or knockout) using GO, KEGG pathway, and PPI analyses.
Main Results:
- MeCP2 was found to be downregulated in a heart failure animal model.
- Ten dysregulated hub genes (JAK1, SETD1B, HRC, TTN, LYZ2, TPM3, MYH11, MYH6, ALOX5AP, DECR1) were identified in relation to MeCP2.
- These genes are primarily enriched in Rho GTPase-mediated cytoskeletal regulation and chemokine/cytokine signaling pathways involved in inflammation.
Conclusions:
- The identified dysregulated genes elucidate the mechanisms underlying MeCP2's role in heart failure.
- These genes may serve as potential therapeutic targets for heart failure.
- The identified genes show promise as prognostic markers for heart failure patients.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
975
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
975
01:17Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
01:27Heart Failure I: Introduction
924
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
924
01:22Heart Failure VI: Adjunct Therapies
368
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
01:22Heart Failure Drugs: Diuretics
990
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
990
01:30Heart Failure V: Medical Management
342
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
342